What is true regarding varicella-containing vaccines?

The assertion that HZV (Zostavax) contains 14 times more antigen than the varicella vaccine is accurate and aligns with the specifics of these vaccines. Zostavax is designed to boost immunity in older adults who have previously been infected with the varicella virus, as they are at higher risk for developing herpes zoster (shingles). To achieve this, Zostavax is formulated with a much higher concentration of the varicella-zoster virus, which is necessary for eliciting a stronger immune response in the older population who may have waning immunity.

The other points do not hold true. For example, Zostavax is not recommended for children; instead, the varicella vaccine is the standard vaccine used in pediatric populations to protect against chickenpox. Moreover, varicella vaccine is specifically formulated for children, while Zostavax is intended for use in adults, particularly those 50 years and older. Additionally, varicella vaccine and HZV are not identical; they serve different purposes, target different populations, and differ in their antigen content and formulation. Understanding these distinctions is crucial for making appropriate recommendations concerning vaccination in different age groups and health statuses.